Nuvaring 11.4 mg (Etonogestrel RING (SLOW-RELEASE)) 11.4 MG

NUVARING 11.4 MG is a vaginal ring designed for hormonal contraception. This slow-release ring contains etonogestrel, offering a convenient method for birth control. Learn more about its uses and effects.

Strength

11.4 MG

Manufacturer / TM Owner

ORGANON CANADA INC.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

NUVARING 11.4 MG is primarily used for birth control. This vaginal ring releases etonogestrel, a progestin hormone, to prevent ovulation and thicken cervical mucus. Many women use this method for its convenience and effectiveness in pregnancy prevention. The ring is inserted into the vagina and left in place for three weeks, followed by a one-week break.

Side Effects

Common effects of NUVARING 11.4 MG may include changes in menstrual bleeding patterns, such as lighter or irregular periods. Some users may experience headaches, breast tenderness, or mood changes. These effects vary among individuals and typically subside as the body adjusts to the hormone.

Precautions & Warnings

NUVARING 11.4 MG should be handled with clean hands to avoid infection. It is important to follow the prescribed schedule for insertion and removal. Women with a history of blood clots, liver disease, or certain cancers should consult a healthcare provider before use. Always store the ring as directed to maintain its effectiveness.

Avoid Interactions

NUVARING 11.4 MG may interact with certain medications, including those that affect liver enzymes. Antibiotic use, particularly rifampin, can reduce the ring's effectiveness. It is advisable to discuss all current medications with a healthcare provider to avoid potential interactions.

Frequently Asked Questions

NUVARING 11.4 MG is used for hormonal contraception, providing a convenient method to prevent pregnancy.

The ring releases etonogestrel, which prevents ovulation and thickens cervical mucus to block sperm.

Common side effects may include changes in menstrual bleeding, headaches, breast tenderness, and mood changes.

NUVARING 11.4 MG is typically used for three weeks, followed by a one-week break before inserting a new ring.

Yes, it may interact with medications that affect liver enzymes, such as certain antibiotics and anticonvulsants.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.